Dermata Therapeutics, Inc.DRMAEarnings & Financial Report
Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.
DRMA Q3 FY2023 Key Financial Metrics
Revenue
$92.8K
Gross Profit
N/A
Operating Profit
$-1.8M
Net Profit
$-1.7M
Gross Margin
N/A
Operating Margin
-1953.3%
Net Margin
-1853.3%
YoY Growth
531.8%
EPS
$-0.54
Dermata Therapeutics, Inc. Q3 FY2023 Financial Summary
Dermata Therapeutics, Inc. reported revenue of $92.8K (up 531.8% YoY) for Q3 FY2023, with a net profit of $-1.7M (up 29.1% YoY) (-1853.3% margin).
Key Financial Metrics
| Total Revenue | $92.8K |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | N/A |
| Operating Margin | -1953.3% |
| Report Period | Q3 FY2023 |
Dermata Therapeutics, Inc. Annual Revenue by Year
Dermata Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $20.6K).
Dermata Therapeutics, Inc. Quarterly Revenue & Net Profit History
Dermata Therapeutics, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2023 | $92.8K | +531.8% | $-1.7M | -1853.3% |
| Q2 FY2023 | $31.1K | — | $-1.7M | -5479.4% |
| Q1 FY2023 | $37.5K | — | $-2.2M | -5967.3% |
| Q4 FY2022 | $42.1K | — | $-1.7M | -3967.0% |
| Q3 FY2022 | $-21.5K | -3400.5% | $-2.4M | 11284.5% |
| Q2 FY2022 | $0 | — | $-2.7M | N/A |
| Q1 FY2022 | $0 | — | $-2.8M | N/A |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $-21486 | $42087 | $37540 | $31050 | $92767 |
| YoY Growth | N/A | N/A | -3400.5% | N/A | N/A | N/A | 531.8% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Assets | $9.0M | $11.0M | $9.0M | $6.9M | $9.3M | $8.7M | $7.3M |
| Liabilities | $1.2M | $1.4M | $1.5M | $922634 | $1.2M | $682862 | $916817 |
| Equity | $7.9M | $9.7M | $7.5M | $6.0M | $8.1M | $8.0M | $6.4M |
Cash Flow
| Q1 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|
| Operating CF | $-2.6M | $-1.8M | $-1.6M |